BioVie Inc. Announces Closing of Public Offering
- None.
- None.
Insights
The closure of BioVie Inc.'s public offering, generating approximately $21 million before fees and expenses, is a significant liquidity event for the company. This capital raise is indicative of the company's proactive approach to funding its operations and research pipeline. The offering's structure, which includes both shares and warrants, provides investors with the potential for future equity participation at a set price, which could be beneficial if the stock appreciates. The immediate exercisability of the warrants at $1.50 suggests confidence in the company's future value, albeit it also implies potential dilution for current shareholders.
From a financial perspective, the use of proceeds for working capital and general corporate purposes is fairly standard. However, the specifics of how this capital will be allocated across BioVie's projects could significantly affect the company's burn rate and runway. Investors should monitor how this influx of capital translates into progress in the company's clinical trials and product development, which could impact the company's valuation and stock performance in both the short and long term.
BioVie's focus on liver disease, neurological and neuro-degenerative disorders places it within highly specialized and competitive segments of the pharmaceutical industry. The company's ability to close a substantial offering suggests investor confidence in its therapeutic prospects. The funding could accelerate the development of BioVie's drug therapies, potentially leading to advancements in treatment options for chronic debilitating conditions.
Given the clinical-stage nature of the company, the capital raised is likely to support ongoing clinical trials, which are critical for securing regulatory approvals and commercialization. The success of these trials will be pivotal for the company's future, as positive outcomes can lead to significant stock appreciation, whereas any setbacks could have the opposite effect. Stakeholders should look for updates on trial progress and interim data, which can serve as indicators of the company's scientific and commercial potential.
From a market perspective, the closing of BioVie's offering at $1.00 per share and associated warrant could be seen as an opportunity for investors to gain exposure to the biotech sector at a relatively low entry point. The biotech industry is known for its volatility and high-risk, high-reward nature. The pricing of the warrants at a 50% premium to the offering price reflects an expectation of growth, which could attract speculative investors.
It is also important to consider the broader industry context. Biotech firms often rely on capital markets to fund research due to the long development timelines and significant costs associated with bringing new drugs to market. Therefore, BioVie's successful capital raise not only supports its individual objectives but also contributes to the overall narrative of investment viability within the biotech sector. Market trends, investor sentiment and the performance of peer companies should be considered when evaluating the potential impact of this offering on BioVie's stock performance.
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock (“Pre-funded Warrants”)and warrants to purchase up to 10,500,000 shares of common stock (the "Common Warrants") at a combined public offering price of
ThinkEquity acted as sole placement agent for the offering.
The securities were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 18, 2023 and declared effective on August 28, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company conducted and reported efficacy data on its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S Food and Drug Administration (“FDA”) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
For Investor Relations Inquiries:
Bruce Mackle
Managing Director, LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
For Media Relations Inquiries:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com
FAQ
How many shares were included in BioVie Inc.'s public offering?
What is the total amount raised by BioVie Inc. through the public offering?
What are the intended uses of the net proceeds from the public offering for BioVie Inc.?
Who acted as the sole placement agent for BioVie Inc.'s public offering?
Where can the final prospectus supplement and accompanying prospectus relating to the offering be obtained?
